Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Predicting the Risk and Severity of Cytokine Release Syndrome in Patients Receiving CAR T-Cell...

While treatment with CD19-directed chimeric antigen receptor (CAR) T cells has demonstrated impressive response rates of over 80% in select patients with B-cell malignancies,...
WIB_icon

Adding Rituximab to Corticosteroids and Cyclosporine A in Patients With cGVHD Improves ORR

Standard firstline treatment for chronic graft-versus-host disease (cGVHD) includes corticosteroids and cyclosporine A, but disease control often requires long-term immunosuppressive treatment, which impairs patients’...
WIB_icon

Examining Ibrutinib as Secondline Therapy for Chronic Graft-Versus-Host Disease

On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved the Bruton tyrosine kinase inhibitor ibrutinib as a secondline treatment for adult...
WIB_icon

Early Study Shows Venetoclax Is Active in Patients With Relapsed/Refractory Myeloma and t(11;14)

Venetoclax, an oral BCL2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of chronic lymphocytic leukemia, may be a treatment...
WIB_icon

Can Genomics Predict Which Patients With Aplastic Anemia Will Develop MDS?

Patients with aplastic anemia (AA) can develop clonal disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and secondary myelodysplastic syndromes (sMDS). “Distinguishing from those...
WIB_icon

Hydroxyurea Treatment Impairs Spermatogenesis in Men With SCA

The prognosis for patients living with sickle cell anemia (SCA) has improved in the past few decades, thanks in part to the availability of...
WIB_icon

Examining Ibrutinib as Secondline Therapy for cGVHD

On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved the Bruton tyrosine kinase inhibitor ibrutinib as a secondline treatment for adult...
WIB_icon

Examining Anemia, Hemolysis Markers, and Vascular Complications of Sickle Cell Disease in Sub-Saharan Africa

Previous studies of patients with sickle cell disease (SCD) suggested that certain patients are at risk for “hyperhemolysis,” characterized by a pattern of lower...
WIB_icon

Hydroxyurea Is Safe, Efficacious in Children With SCA Living in Malaria-Endemic Sub-Saharan Africa

In vitro and animal studies suggest that hydroxyurea – one of two treatments approved by the U.S. Food and Drug Administration for the treatment...
WIB_icon

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...
Advertisement

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.